Danaher (NYSE:DHR - Get Free Report) was downgraded by equities research analysts at Rothschild Redb from a "strong-buy" rating to a "hold" rating in a research note issued to investors on Wednesday,Zacks.com reports.
A number of other equities research analysts have also recently weighed in on the company. Evercore ISI upped their price objective on Danaher from $226.00 to $245.00 and gave the stock an "outperform" rating in a research note on Tuesday. Rothschild & Co Redburn reaffirmed a "neutral" rating and set a $220.00 target price (down from $245.00) on shares of Danaher in a research report on Wednesday. Barclays reaffirmed an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Guggenheim reaffirmed a "buy" rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Finally, Wells Fargo & Company reduced their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $244.60.
Get Our Latest Stock Analysis on DHR
Danaher Trading Down 0.3%
DHR opened at $204.31 on Wednesday. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The firm has a market cap of $146.29 billion, a price-to-earnings ratio of 43.47, a PEG ratio of 2.92 and a beta of 0.77. Danaher has a 12 month low of $171.00 and a 12 month high of $279.41. The stock has a fifty day moving average price of $200.55 and a 200-day moving average price of $197.32.
Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts anticipate that Danaher will post 7.63 earnings per share for the current fiscal year.
Insider Buying and Selling at Danaher
In other news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 11.10% of the company's stock.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Norges Bank purchased a new stake in Danaher in the 2nd quarter worth approximately $1,979,503,000. Nuveen LLC purchased a new stake in Danaher in the 1st quarter worth approximately $833,941,000. Viking Global Investors LP boosted its position in Danaher by 543.9% in the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate's stock worth $574,351,000 after purchasing an additional 2,455,994 shares in the last quarter. Generation Investment Management LLP grew its holdings in Danaher by 56.2% in the second quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate's stock valued at $980,914,000 after purchasing an additional 1,787,522 shares during the period. Finally, Invesco Ltd. grew its holdings in Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.
About Danaher
(
Get Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.